Abstract
The platelet receptor glycoprotein (GP)Ib-IX-V complex plays a dominant role in the first steps of platelet adhesion and arterial thrombus formation. Through its interaction with the multimeric plasma protein von Willebrand factor (VWF), which is bound to the damaged subendothelial structures, GPIb-IX-V tethers the platelets from the flowing blood thereby slowing them down. This step is a prerequisite for the collagen receptors to participate in firm adhesion resulting in the formation of a first platelet layer which is the basis for further thrombus formation. Recently, other ligands for GPIb-IX-V besides the extensively studied VWF have been identified, such as : α-thrombin, coagulation factor XII (FXII), high molecular weight kininogen (HMWK), factor XI (FXI), integrin Mac-1 and P-selectin. In this review, the interaction of GPIb-IX-V with its different ligands is described and the anticipated or demonstrated in vivo effects are discussed.
Keywords: Glycoprotein Ib, platelets, antithrombotic agents
Current Pharmaceutical Design
Title: Inhibition of Platelet Glycoprotein Ib and Its Antithrombotic Potential
Volume: 13 Issue: 26
Author(s): Karen Vanhoorelbeke, Hans Ulrichts, Gerlinde Van de Walle, Alexandre Fontayne and Hans Deckmyn
Affiliation:
Keywords: Glycoprotein Ib, platelets, antithrombotic agents
Abstract: The platelet receptor glycoprotein (GP)Ib-IX-V complex plays a dominant role in the first steps of platelet adhesion and arterial thrombus formation. Through its interaction with the multimeric plasma protein von Willebrand factor (VWF), which is bound to the damaged subendothelial structures, GPIb-IX-V tethers the platelets from the flowing blood thereby slowing them down. This step is a prerequisite for the collagen receptors to participate in firm adhesion resulting in the formation of a first platelet layer which is the basis for further thrombus formation. Recently, other ligands for GPIb-IX-V besides the extensively studied VWF have been identified, such as : α-thrombin, coagulation factor XII (FXII), high molecular weight kininogen (HMWK), factor XI (FXI), integrin Mac-1 and P-selectin. In this review, the interaction of GPIb-IX-V with its different ligands is described and the anticipated or demonstrated in vivo effects are discussed.
Export Options
About this article
Cite this article as:
Vanhoorelbeke Karen, Ulrichts Hans, de Walle Van Gerlinde, Fontayne Alexandre and Deckmyn Hans, Inhibition of Platelet Glycoprotein Ib and Its Antithrombotic Potential, Current Pharmaceutical Design 2007; 13 (26) . https://dx.doi.org/10.2174/138161207781662867
DOI https://dx.doi.org/10.2174/138161207781662867 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Protection, Repair and Regeneration of Achybreaky Heart)
Current Drug Targets Role of Poly(ADP-ribose) Polymerase (PARP1) in Viral Infection and its Implication in SARS-CoV-2 Pathogenesis
Current Drug Targets Cellular and Pharmacological Targets to Induce Coronary Arteriogenesis
Current Cardiology Reviews Cellular Actions of Nesfatin-1 on Hypothalamic and Medullary Neurons
Current Pharmaceutical Design Protective Effect of Vitamin B Therapy on Bone and Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Neuroprotective Effects of Intravenous Anesthetics: A New Critical Perspective
Current Pharmaceutical Design Targeted Delivery of Montelukast for the Treatment of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Molecular Targets of Diabetic Vascular Complications and Potential New Drugs
Current Drug Targets Long Noncoding RNA OIP5-AS1 Overexpression Promotes Viability and Inhibits High Glucose-Induced Oxidative Stress of Cardiomyocytes by Targeting MicroRNA-34a/SIRT1 Axis in Diabetic Cardiomyopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets EGF Receptor as a Drug Target in Arterial Hypertension
Mini-Reviews in Medicinal Chemistry Carvedilol: Just Another Beta-Blocker or a Powerful Cardioprotector?
Cardiovascular & Hematological Disorders-Drug Targets Contrast Echocardiography: An Update on Clinical Applications
Current Pharmaceutical Design Disruption of Zinc Neuromodulation by Aß Oligomers : Therapeutic Implications
Current Pharmaceutical Design The Coronary Collateral Circulation in Man
Current Cardiology Reviews Brain Permeable Nanoparticles
Recent Patents on CNS Drug Discovery (Discontinued) Pro- and Anti-Arrhythmic Effects of Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Repetitive Transient Phosphodiesterase-3 Inhibition Eliminates Non-ischemic Cardiac Remodeling and Failure
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Anthocyanins As Modulators of Cell Redox-Dependent Pathways in Non-Communicable Diseases
Current Medicinal Chemistry Pharmacological Potential of Tetrahydrofurano/Pyrano Quinoline and Benzo[b]furoindolyl Derivatives in Acute Inflammation, Pain and Oxidative Stress
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Antioxidant Effects of Radix Astragali (Astragalus membranaceus and Related Species) in Protecting Tissues from Injury and Disease
Current Drug Targets